Published in Blood Weekly, June 17th, 1996
The study will evaluate the safety and hematopoietic activity of repeated low doses of rHb1.1 in approximately 50 patients with anemia resulting from End Stage Renal Disease (ESRD).
The randomized, double-blind, placebo-controlled trial is a dose-ranging study conducted at five sites within the United States. Participants in the trial have been on hemodialysis for six months or more, and have responded to treatment with exogenous erythropoietin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.